Endoscopic resection has become the first-line therapy for the management of superficial neoplasia throughout the gastrointestinal tract. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are established yet distinct techniques for the treatment of superficial gastrointestinal neoplasia. EMR is simpler and faster but is limited by its ability to resect large lesions en bloc. Limitations of piecemeal EMR of large lesions include a high rate of recurrence and a less-than-ideal tissue specimen for accurate histologic evaluation. ESD, on the other hand, allows en bloc resection regardless of lesion size, reducing risk for recurrence and facilitating precise histologic staging. However, ESD can take longer than EMR, is technically more complex, and traditionally has been associated with a higher rate of adverse events. Ultimately, the optimal endoscopic technique should be selected based on organ location, type of neoplastic lesion, and local expertise. The role of ESD has expanded in Eastern regions, beyond squamous cell lesions in the esophagus and gastric cancer to include superficial Barrett's esophagus (BE) and colon neoplasia. However, there is controversy in Western regions over use of ESD for BE and colon neoplasia. We discuss the clinical outcomes of EMR and ESD for the treatment of superficial BE and colon neoplasia, focusing on practical considerations for formulating the most appropriate endoscopic resection approach for each patient.
T he detection of dysplastic and early gastrointestinal (GI) cancer lesions has increased over recent years as a result of the concerted effort and adoption of endoscopic screening and surveillance programs. 1 With advances in endoscopic techniques, the vast majority of these lesions can be managed adequately by endoscopy. Endoscopic mucosal resection (EMR) is an effective and safe technique for the removal of neoplastic lesions in both the upper and lower GI tract. The main limitation of EMR is the inability to resect large lesions en bloc, which can increase the risk of recurrence and hinder histopathologic examination. 2 Endoscopic submucosal dissection (ESD) is an alternative technique that was developed in Japan specifically for the en bloc resection of GI neoplastic lesions regardless of their size. The advantages of ESD over EMR for select lesions has led to its routine application in Asia, but it has yet to be widely accepted in the West. The main obstacles precluding the adoption of ESD in the West include a steeper learning curve, a lengthier procedure, and a higher potential for adverse events. 3 Nonetheless, evidence on ESD for the management of GI neoplasia continues to amount and has led to an intensified effort for its implementation in Western countries.
Endoscopic Resection For Barrett's Esophagus-Associated Lesions
Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC) and follows a well-established progression from nondysplastic BE, through low-grade to high-grade dysplasia. 4 Currently, endoscopic therapy is a cost-effective, minimally invasive, first-line treatment for BE-associated neoplasia, with lower complication rates when compared with surgery. Although EMR is the most common technique for endoscopic resection in BE-associated neoplasia, the growth in the field of ESD potentially expands the reach of curative endoscopic therapy and may represent a preferred strategy in select cases. 5 In this section, we discuss clinical outcomes of EMR and ESD for the treatment of BEassociated neoplasia and focus on specific issues to be addressed when formulating the most appropriate individualized endoscopic resection approach.
guide subsequent therapy based on the grade of dysplasia and depth of invasion. 5 EMR can be curative in patients with low-risk superficial esophageal neoplasia. 6 Overall, the recurrence rate of dysplasia after curative EMR is estimated to be between 6% and 10%. 7 Factors associated with recurrence after curative EMR for superficial esophageal neoplasia include the following: (1) piecemeal resection, (2) when ablation is not performed, and (3) in long-segment BE. 8 These results further highlight the need for ablation therapy of any concomitant flat BE mucosa after localized EMR of the target area. 9 One of the main disadvantages of EMR is that for lesions greater than 15 mm, piecemeal resection usually is necessary. This, in turn, inevitably yields a fragmented pathologic specimen, potentially compromising histopathologic evaluation for curative resection. 10 The aim of endoscopic therapy is to achieve cure. For lesions with SMI, surgery still can be avoided and endoscopic resection is considered curative if all of the following criteria are met: (1) resection margins are negative (R0 resection), (2) depth of invasion is less than 500 mm below the muscularis mucosae (superficial SMI), (3) absence of poorly differentiated or mucinous histology, and (4) absence of lymphovascular involvement. Conversely, an advantage of EMR over surgery is its safety profile. Bleeding and perforation are rare, whereas stricture formation is more common after wide-field piecemeal EMR. 11, 12 Importantly, in most cases, adverse events can be successfully managed endoscopically without the need for surgery. 12 
Endoscopic Submucosal Dissection
ESD was introduced in Japan in 1988 for the treatment of early gastric cancer. 13 The main advantage of ESD over EMR is that it allows en bloc resection of any lesion irrespective of size, thereby providing an ideal specimen for accurate histopathologic evaluation of both lateral and deep margins. Therefore, in its core, ESD aligns with well-established oncologic resection principles and rapidly has expanded to include the treatment of early squamous cell cancer of the esophagus and colonic neoplasia. 14, 15 Conversely, ESD as a therapy for BE-associated neoplasia has lagged, mostly because of the rather low incidence of BE in the East. Recently, however, expanding evidence from Europe and the United States has shed light on the potential role of ESD in the management of BE-associated neoplasia.
We recently performed a meta-analysis of 11 studies on the efficacy and safety of ESD in a total of 524 lesions of BE-associated neoplasia. 16 The mean lesion size was 27 mm, and the average procedure time was 108 minutes. The pooled en bloc resection rate was 93%, whereas those for R0 and curative resection were 74.5% and 64.9%, respectively. On logistic regression, R0 and curative resection rates were not found to be associated with study origin (Asia vs Europe/United States), length of BE segment, lesion characteristics (size or morphology based on Paris classification), procedural time, or length of follow-up evaluation. Adverse events, including bleeding (1.7%) and perforation (1.5%), were rare. Esophageal stricture formation was reported in 11.6%, with all cases managed successfully with endoscopic dilation. In aggregate, the estimated recurrence rate for BE-associated neoplasia after curative resection was 0.17% at a mean follow-up period of 22.9 months. 16 The safety profile of ESD appears to be favorable, with most adverse events treated successfully with endoscopy alone. 16, 17 Similar to wide-field EMR, stricture formation remains 1 of the main obstacles to the widespread use of ESD and is related directly to the extent of the resection. 16, 18, 19 Serial endoscopic dilations remain the mainstay therapy, but steroid administration via different routes may provide some additional benefit. 19, 20 Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection for Barrett's-Associated Neoplasia There are only a few studies comparing outcomes between EMR vs ESD for BE-associated neoplasia. 21 A meta-analysis evaluating the effectiveness of EMR vs ESD for superficial EAC, which included 1080 patients, reported a higher en bloc resection rate with ESD (97.1%) than EMR (49.3%), irrespective of the diameter of the lesion (P < .001). Importantly, ESD achieved a higher curative rate (92.3% with ESD vs 52.7% with EMR; P < .001), and a lower incidence of local recurrence (0.3% with ESD vs 11.5% with EMR; P < .001). Not surprisingly, the procedure length was longer with ESD compared with EMR. The risk of bleeding and stricture formation was similar between the 2 groups, whereas the perforation rate was higher for ESD than EMR (odds ratio [OR], 2.2; 95% CI, 1.08-4.47; P ¼ .03). 21 Another systematic review and meta-analysis of 16 studies reported that although multiband EMR was less time consuming (mean, 36.7 min) than ESD (mean, 83.3 min), the lesion sizes removed with EMR (range, 1-30 mm) also were smaller than those treated with ESD (range, 14-85 mm). 22 The incidence of adverse events was similar between the 2 groups. A trend for higher recurrence rate after EMR (2.6%) compared with ESD (0.7%) was noted but did not quite reach statistical significance (OR, 8.55; 95% CI, 0.91-80; P ¼ .06). 22 In a prospective randomized controlled study comparing multiband EMR with ESD in 40 patients with BE and superficial esophageal neoplasia, the en bloc resection rate was significantly higher with ESD when compared with EMR (100% vs 15%; P < .0001). 23 The mean procedure times for EMR and ESD were 22 and 54 minutes, respectively; however, the mean maximal diameter of the resected specimen was significantly larger in the ESD group (29 vs 18 mm; P < .0001). Curative resection, including cases of EAC limited to the superficial submucosa without other advanced features, was achieved in 53% of patients undergoing ESD but only in 12% of those treated with EMR (P ¼ .03). 23 Based on these results, recurrence of BE-associated neoplasia would have expectantly been less frequent in patients who underwent ESD; albeit, this was not evaluated specifically in this study. Finally, the investigators reported no difference in complete remission between the 2 groups at the 3-month follow-up evaluation. Bleeding and perforation rates also were similar in both groups. 23 A Proposed Guide to Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection in Barrett's-Associated Neoplasia: Practical Considerations Endoscopic resection techniques target lesions within the BE segment that are confined to the mucosa (eg, dysplasia, intramucosal cancer) or select EAC lesions limited to the superficial SMI. Endoscopic therapy is appropriate only for lesions with either no risk or an anticipated very low risk of lymph node metastasis. Table 1 summarizes the relationship between depth of invasion and the risk of lymph node metastasis for esophageal lesions. [24] [25] [26] [27] Predictors of lymph node metastasis include poorly differentiated histology, presence of lymphovascular invasion, and deep submucosal involvement. 8, 28 Hence, meticulous lesion characterization is essential before selecting the most appropriate resection strategy.
Multiple factors, including patient preference, play a role when choosing the most appropriate individualized therapy. Furthermore, it is important to emphasize that the decision to pursue ESD also should depend on local expertise because ESD still is not available for BE at most institutions in the United States. Although ESD is technically feasible and safe, it has not been shown to be superior to EMR for the excision of dysplasia or superficial EAC. Therefore, at present, EMR of target lesions followed by ablation of flat BE remains the first-line therapy. The European guidelines recommend ESD for select cases, such as lesions larger than 15 mm, poorly lifting tumors, and lesions at risk for SMI. 29 We want to propose and further expand on the following variables when selecting EMR vs ESD.
Lesion Size. EMR is limited by the diameter of the cap fitted over the endoscope, usually restricting en bloc resection of lesions less than 15 to 20 mm. Larger lesions must be removed in piecemeal fashion, resulting in fragmented specimens, making histologic assessment for curative resection difficult, if not impossible. In turn, this potentially could lead to unnecessary surgery given the lack of confirmation of margin-free neoplasia. In contrast, ESD offers en bloc resection regardless of lesion size, allowing accurate assessment of the specimen's lateral and deep margins. 10 Considering this superior histopathologic assessment of the ESD specimen, it comes as no surprise that 2 recent US studies showed that ESD upstaged the dysplasia diagnosis in 55% of patients. 30, 31 Hence, we support the recommendations from the European guidelines and often resort to ESD for the removal of large lesions, particularly if they are more than 15 mm in size.
Macroscopic Appearance. ESD should be considered for bulky (Paris Is, Ip) or slightly depressed lesions (Paris IIc) given the higher risk of SMI in these select cases ( Figure 1 ). 32 Index Histopathology. Discrepancy frequently is encountered between the index histology obtained by biopsy and the final EMR or ESD specimen. This likely is owing to sampling error and the limited amount of tissue obtained by forceps biopsy. Importantly, the final histopathologic assessment of the resected specimen typically is upstaged when compared with the initial biopsy evaluation. 30, 31 Therefore, lesions showing intramucosal carcinoma (particularly multifocal intramucosal carcinoma) or at least intramucosal carcinoma should be considered for ESD. NOTE. m1 involves the epithelium without breaching the lamina propria; m2 extends into the lamina propria with intact muscularis mucosa; and m3 invades the muscularis mucosa but without submucosal involvement; the sm1 lesion extends into the upper one third of the submucosa; the sm2 lesion extends into the middle one third of the submucosa; and the sm3 lesion invades the lower one third of the submucosa. m, mucosa; sm, superficial mucosa. based on an EMR specimen showing positive lateral or deep margins on histopathology, can be approached with ESD because repeat EMR often is complicated by scarring. ESD can provide a wider en bloc resection field to facilitate evaluation and confirmation of complete removal of any residual disease. This approach is particularly appealing in nonsurgical candidates. Cost Effectiveness. ESD is a lengthier procedure than EMR and is associated with higher periprocedural morbidity. Furthermore, when compared with EMR, which commonly is completed in the outpatient setting, many patients often are admitted after ESD for routine observation. In our current health care system aimed at maintaining care while restraining expenditure, these differences would suggest short-term incremental costs with ESD and can be viewed as a deterrent to its adoption in the West. However, it is conceivable that in the future, with the maturation of ESD and the development of structured training programs, some of these cost differences may be mitigated by reduced perioperative complications and shorter surgical times. ESD is associated with a higher R0 resection rate and lower risk of recurrence when compared with EMR. In the long term, this could prove to be cost effective because it theoretically may reduce the need for additional endoscopic interventions.
A suggested management algorithm for BE-related neoplasia is summarized in Figure 2 .
Endoscopic Resection of Colorectal Lesions
The early identification and removal of colon polyps has been shown to reduce the risk of death from colorectal cancer. 33 Presently, endoscopic resection is the preferred first-line treatment of most colorectal lesions given its associated lower cost, morbidity, and mortality when compared with surgery. 34, 35 In this section, we discuss clinical outcomes of EMR and ESD for the treatment of colorectal lesions and address specific points and practical considerations when evaluating the endoscopic resection strategy for any given case.
Endoscopic Mucosal Resection
EMR is effective and safe for the management of most colorectal lesions. In a prospective observational study of 1134 consecutive patients with mean lesion size of 36.4 mm, EMR was completed successfully in 91.3% of the cases. 36 A recent meta-analysis further supports endoscopic resection as safe and effective for complex colon polyps, sparing the need for surgery in more than 90% of cases. 37 Furthermore, in comparison with surgery, EMR is less costly, associated with higher patient satisfaction, and fewer complications. 35, 38, 39 As such, EMR has become not only an accepted alternative to surgery, but is the first-line therapy for the management of most precancerous colon polyps.
The main limitation of EMR is the risk of recurrence associated with piecemeal resection. Piecemeal EMR has been associated with varying rates of residual or recurrent adenoma, ranging from 7% to 40%. 36, [40] [41] [42] The factors responsible for polyp recurrence after piecemeal EMR are not completely understood, but incomplete resection appears to be at the heart of the problem. Bahin et al 43 showed that extending the lateral resection margins during EMR did not reduce the rate of residual/ recurrent adenoma, yet increased the risk of bleeding. This further underscores the concept that recurrence may not be owing exclusively to incomplete resection at the outer margins of the lesion, but perhaps more importantly, from microscopic residual tissue at the margins of each resection during piecemeal EMR.
Piecemeal EMR hinders histopathologic analysis, which is another drawback of EMR of large colorectal lesions. The aim of endoscopic therapy is to achieve cure. For lesions with SMI, surgery still can be avoided and endoscopic resection is considered curative if all of the following criteria are met: (1) resection margins are negative (R0 resection), (2) depth of invasion is less than 1000 mm below the muscularis mucosae (superficial SMI), (3) absence of poorly differentiated or mucinous histology, and (4) absence of lymphovascular involvement and tumor budding. 44 To evaluate for curative resection, a lesion must be excised completely, which Figure 2 . Proposed algorithm on how to choose between EMR or ESD for BE-associated neoplasia.
entails negative lateral and deep margins on histopathology evaluation. This often can be a difficult if not impossible task with piecemeal resection. The fragmented tissue specimens with piecemeal EMR often curl at the edges, significantly compromising specimen orientation and interpretability of where the lateral margin ends and the deep margin begins. Hence, patients with endoscopically curable lesions with SMI who undergo piecemeal EMR inevitably still will require surgery because of the high risk of understaging the lesion owing to compromised pathologic interpretation. 45 EMR has a favorable safety profile with a low incidence of serious adverse events. Delayed bleeding is the most common adverse event with EMR. Most cease spontaneously, whereas severe delayed bleeding, which occurs in up to 7% of patients, often can be managed adequately with transfusions and/or repeat endoscopic therapy. 46 Lesion in the right colon, use of anticoagulation agents, age older than 65 years, medical comorbidities, and the use of electrocautery not controlled by a microprocessor are factors associated with an increased risk of bleeding. 46 Prophylactic coagulation of exposed visible vessels has not been shown conclusively to reduce the risk of bleeding. 47 The overall risk of colonic perforation with EMR is approximately 1.1%, with clinically significant perforation, defined as that requiring surgery, occurring in 0.5% of cases. 34, 48 The spectrum of injuries to the muscularis propria during EMR often can be treated by reinforcing the muscle wall or closing the defect with clips or endoscopic suturing. Routine closure of all EMR defects; however, has not been studied adequately and remains a topic of ongoing debate.
Endoscopic Submucosal Dissection
As previously discussed, ESD initially was developed in Japan as a minimally invasive alternative to surgery for the treatment of early gastric cancer. Given its efficacy and safety in the hands of Japanese experts, ESD has been expanded in Asia to include colorectal lesions. After initial submucosal injection to establish a safe resection plane by separating the target lesion from the underlying colonic muscularis propria, ESD is performed by precise electrosurgical dissection within the deep submucosa.
Early case series on colorectal ESD reported en bloc resection rates of approximately 80%, but perforation rates occurring in up to 10% in some studies. 49 However, with refinement of the technique, coupled with the development of dedicated ESD devices, has paid dividends over the years by translating into improved outcomes, as illustrated in subsequent larger case series. In a multicenter prospective observational study, Saito et al 50 reported en bloc and curative resection rates of 88% and 89%, respectively, for 1111 colorectal lesions treated with ESD. Perforations occurred in 54 cases (4.9%), of which only 5 patients required surgical intervention. Large tumor size (50 mm) and low volume of ESD cases were associated with increased risk for adverse events. Subsequent studies from Asia have reported similar outcomes, with en bloc resection rates between 90% and 98% and perforation occurring between 2.5% to 5%. 51, 52 Procedure duration, one of the perceived limitations of colorectal ESD, also has improved with the maturation of the technique in Asia. In a study of 150 ESD cases, Nawata et al 53 reported a median procedure time of 38 minutes for lesions with a median resected specimen size of 35 mm. More recently, a modified pocket-creation ESD method was introduced. 54, 55 In contrast to conventional ESD, in which a circumferential mucosal incision is performed before submucosal dissection, the pocket ESD technique relies on completing most of the submucosal dissection through a small mucosal opening. Sakamoto et al 56 recently showed how this modified technique was associated with both a higher en bloc resection rate and faster procedure time when compared with conventional ESD for laterally spreading nongranular tumors. This is a prime example of how colorectal ESD continues to evolve with improved clinical outcomes and procedural parameters.
The transition of colorectal ESD to the West has been slower than its uptake in Asia, particularly because of the steep learning curve associated with this technique and the low incidence of gastric cancer in the West, which has limited the training opportunities for endoscopists interested in ESD. Therefore, it comes as no surprise that initial outcomes of colorectal ESD in the West have not met the same benchmarks as those established in Asia. Fuccio et al 57 recently conducted a systematic review and meta-analysis evaluating clinical outcomes of ESD in 18,764 colorectal lesions. The pooled en bloc and R0 resection rates for ESD were 91% and 82%, respectively. However, when compared with Asian countries, the R0 resection rate was significantly lower in non-Asian countries (71.3% vs 85.6%; P < .001), with a higher incidence of delayed bleeding (2.4% vs 4.2%; P < .001) and perforation (4.5% vs 8.6%; P < .001). These results further underscore the importance of structured training programs and the need to establish specialized centers in the West for practice standardization.
Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection for Colonic Neoplasia
Multiple studies have compared clinical outcomes between EMR and ESD, but direct comparison by randomized controlled trials are scarce. Fujiya et al 14 conducted a meta-analysis of 8 studies on colorectal neoplasms treated with either EMR or ESD. The size of the tumor and rate of en bloc and curative resection were higher, and the rate of recurrence was lower with ESD vs EMR. However, ESD was associated with a longer procedure and increased rate of perforation. The need for additional surgery was higher in patients who underwent ESD vs EMR, with deep SMI on histopathologic analysis being the most commonly cited reason. Similarly, a separate systematic review of 66 studies involving nearly 18,000 lesions showed a significantly higher pooled en bloc resection rate with ESD (91%) vs EMR (63%) (P < .0001), with the likelihood of recurrence considerably higher in patients who underwent EMR (OR, 8.2; 95% CI, 6.2-10.9; P < .0001). 58 There was no difference in the incidence of delayed bleeding between ESD and EMR, but perforation was seen more commonly with ESD (4.8% vs 0.9%; P < .0001). Similar results have been reported in yet another systematic review and meta-analysis involving 4678 patients. 59 Limitations of these analyses in aggregate include a high degree of heterogeneity among the relatively small number of studies, composed predominantly of case series.
A Proposed Guide to Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection in Colorectal Lesions: Practical Considerations
The ideal endoscopic approach should be one that is cost effective, is associated with a high rate of curative resection, has an acceptable risk profile, minimizes the need for recurrent interventions, and, ultimately, avoids surgery. Neither EMR nor ESD alone will meet all of these criteria and therefore the most suitable technique for any given case needs to be individualized. We hereby propose an algorithm (Figure 3 ) based on important factors to consider when choosing the most appropriate endoscopic technique and by incorporating recent guidelines from both the Japan Gastroenterological Endoscopy Society (JGES) and the European Society of Gastrointestinal Endoscopy (ESGE) ( Table 2) . 29, 44 Cost Effectiveness. As discussed in the BE neoplasia section, ESD is a technically more challenging procedure than EMR and traditionally has been associated with higher serious adverse events. This in turn results in longer procedural times and often the need to admit patients for observation after ESD, which can increase health-related costs. On the other hand, the potentially higher curative rate with ESD and lower recurrence rate may impact subsequent costs associated with the need for re-treatment and surveillance. There are currently no established guidelines clearly outlining the optimal surveillance interval after colorectal EMR or ESD, which is based mainly on expert opinion. However, given the high local residual/recurrence rates after piecemeal EMR when compared with en bloc resection; repeat colonoscopy generally is recommended within a 3-to 6-month period. 29, 44 We speculate that confirmation of cure, based on an adequate en bloc histologic specimen, may reduce the need for surveillance after resection and limit costs. Indeed, a multicenter randomized clinical trial evaluating the cost effectiveness of ESD against EMR is underway and the results are awaited eagerly. 60 Curative Resection. The main advantage of ESD over EMR is the potential of en bloc resection of any lesion irrespective of size. Proponents of EMR will emphasize that incomplete piecemeal resection with recurrence is largely inconsequential because it is usually unifocal, diminutive, and easily can be managed endoscopically on subsequent sessions. 36 Indeed, Moss et al 36 showed that most lesions (98%) without SMI on index EMR remain adenoma-free at 16 months. Hence, one can argue that EMR remains the preferred approach in the West for the majority of colonic lesions. EMR safely and effectively can remove lesions en bloc up to 20 mm in size, and piecemeal resection of larger lesions also is acceptable in most cases. However, this approach may be less desirable when dealing with lesions potentially harboring SMI, reportedly occurring in the range of 4% to 11% in the West (Figure 4) . 37, 61 In these select cases, en bloc resection is mandatory for accurate histopathologic assessment because piecemeal resection of endoscopically curable lesions still would subject the patient to unwarranted surgery. Hence, detailed preoperative endoscopic assessment targeting features associated with SMI is critical when choosing between EMR and ESD.
Lesion location and size. Increasing lesion size and location are recognized factors associated with SMI. In a prospective cohort study of 2277 colorectal lesions, rectosigmoid location and increasing lesion size were independent risk factors associated with SMI. 62 Hence, both lesion location and size should serve as important initial parameters when choosing the most appropriate endoscopic resection technique. EMR should be favored over ESD for small colonic lesions with low risk of SMI, particularly given its faster surgical time and lower rate for serious adverse events. Conversely, the JGES recommends the use of ESD for large lesions in which en bloc resection is feasible whereas the ESGE favors ESD of large lesions (>20-30 mm) limited to the rectum, given the favorable safety profile in the distal colon compared with other sites (Table 2) .
Gross morphology. Large nonpedunculated lesions measuring 10 mm or larger in diameter commonly are referred to as lateral spreading tumors (LSTs). LSTs can be granular, with a carpeted nodular surface, or nongranular (LST-NG), with a smooth surface ( Figure 5 ). Recognizing this morphologic distinction is important before endoscopic resection. Most granular LSTs are superficial with a low risk of SMI, and thereby can be resected with EMR. Conversely, the prevalence of SMI is higher in LST-NG, with approximately 30% to 56% of LST-NG having evidence of SMI, primarily limited to the superficial submucosa. 60 Hence, en bloc resection is preferable for these lesions for adequate histologic assessment of the deep margins. Based on these findings, both the JGES and ESGE guidelines recommend that ESD should be considered for the removal of LST-NG where superficial SMI is suspected (Table 2) .
Surface pattern. Multiple classification systems, including the Kudo, Japan Narrow Band Imaging Expert Team, and the Narrow-Band Imaging International Colorectal Endoscopic classifications, rely on a combination of high-magnification imaging and/or chromoendoscopy and/or narrow band imaging to evaluate lesion surface pit structure and vascular pattern. [63] [64] [65] [66] In conjunction with other gross morphologic features, careful surface pattern assessment is imperative during preoperative evaluation to accurately predict lesions most suitable for endoscopic resection.
Safety Profile. The higher perforation rate of ESD compared with EMR has been a concern and barrier for its dissemination in the West. However, with advances in endoscopic closure devices (eg, through-the-scope and over-the-scope clips, endoscopic suturing), most of these complications can be managed endoscopically, with only 1% of cases requiring subsequent surgical intervention. 67 Nonetheless, the colon remains one of the most difficult locations for ESD because of its relatively thinner wall compared with other locations in the GI tract, luminal angulation, and the convergence of mucosal folds in the plane of dissection. Given the safety and efficacy of EMR for the removal of most colorectal lesions, ESD should be reserved for the management of lesions where SMI is suspected. ESD may be most suitable for resection of advanced lesions in the rectum given the higher risks and morbidity associated with surgery in this location relative to the right colon ( Figure 2) .
Need for Recurrent Interventions. Ideally, all colorectal lesions should be removed en bloc when feasible. Piecemeal EMR is associated with a risk of residual/ recurrent polyps, thereby requiring repeated interventions. As previously noted, limitations of this strategy include the following: (1) increasing costs of additional treatment, (2) potential risk of progression from under-recognition of residual/recurrent lesions, and (3) the burden of repeated invasive procedures on the patient. Furthermore, scarring at the site of residual/ recurrent disease may preclude subsequent EMR attempts. Both the JGES and ESGE guidelines propose ESD as a potential salvage therapy in these particular cases (Table 1) . Nonetheless, this strategy should be limited to high-volume specialized centers and not advocated universally, given the recognized increased risk of complications of ESD in the setting of submucosal fibrosis (Figure 2 ). 37 Need for Surgery. EMR is the preferred approach to most benign colorectal lesions. For lesions with superficial SMI and thereby a low risk of lymph node metastasis, ESD offers potential endoscopic cure and may reduce the need for surgery (Table 3) . 24, 68 However, current data have not shown conclusively that patients who undergo ESD vs EMR have a lower rate of additional surgery. 14, [56] [57] [58] Many critics attribute this to the narrow window of lesions with low-risk features and superficial SMI that actually may benefit from ESD. However, the effect of ESD may be underestimated because of the potential for selection bias resulting from discrepancies in the indications for resection and lesion morphology among cases referred for ESD vs EMR. 69 This further underscores the need for high-quality comparative studies between these techniques, and perhaps even more importantly, ongoing research on endoscopic imaging to accurately risk-stratify lesions before resection.
Conclusions
Advanced endoscopic resection techniques have become the first-line treatment of most superficial neoplastic lesions in the GI tract. EMR is a proven safe and effective therapy for the resection of most lesions. The main drawbacks of EMR are that piecemeal resection limits accurate histopathologic evaluation of complete excision when SMI is present and is associated with a risk for recurrence. ESD is an emerging technique associated with higher en bloc resection and lower recurrence rates when compared with EMR. ESD is curative for lesions with superficial SMI and favorable histologic features. A steep learning curve, lengthy procedure, and higher adverse event rates when compared with EMR emphasize the need for structured training programs before its widespread adoption in the West. Both EMR and ESD should be regarded as nonmutually exclusive but rather complementary strategies for the treatment of superficial GI neoplasia. Ultimately, the interplay between lesion characteristics, patient's goals of care, and local expertise availability should dictate the optimal strategy for each individual case. NOTE. m1 involves the epithelium without breaching the lamina propria, m2 extends into the lamina propria with intact muscularis mucosa, and m3 invades the muscularis mucosa but without submucosal involvement; and the sm1 lesion extends into the upper one third of the submucosa; the sm2 lesion extends into the middle one third of the submucosa; and the sm3 lesion invades the lower one third of the submucosa. m, mucosa; sm, superficial mucosa. Adapted from Eleftheriadis et al. 24 
